Abstract
We report on the case of a patient with a diagnosis of a HER2-overexpressing metastatic breast cancer which was refractory to a combination of a Raf kinase inhibitor and docetaxel, but highly sensitive to trastuzumab, a HER2-targeted monoclonal antibody. Interestingly, there was no evidence of Ras-Raf-MAPK or PI3K-Akt pathways activation.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / immunology
-
Drug Resistance, Neoplasm
-
Female
-
Genes, ras
-
Humans
-
Middle Aged
-
Mitogen-Activated Protein Kinase Kinases
-
Phosphatidylinositol 3-Kinases
-
Receptor, ErbB-2 / genetics
-
Trastuzumab
-
Treatment Outcome
-
raf Kinases
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Phosphatidylinositol 3-Kinases
-
Receptor, ErbB-2
-
raf Kinases
-
Mitogen-Activated Protein Kinase Kinases
-
Trastuzumab